PR PolyResearch

Join Free

NASDAQ

Precision BioSciences, Inc. (DTIL)

♥ 541 Thanks from members

Precision BioSciences (DTIL) displays a stark divergence: groundbreaking Phase 1 cccDNA elimination data for its gene-editing pipeline contrasting sharply with lowered revenue expectations, a widened Q2 net loss, and conservative analyst estimates for the remainder of 2026.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Other Nasdaq Tickers

GraniteShares 2x Long AAPL Daily ETF (AAPB)

Apple Inc. (AAPL)

Direxion Daily AAPL Bear 1X ETF (AAPD)

Ascentage Pharma Group International - American Depository Shares (AAPG)

Direxion Daily AAPL Bull 2X ETF (AAPU)

Rocket Pharmaceuticals, Inc. - Warrant (RCKTW)